Skip to content
Peptigraph home

Is Tirzepatide Legal? FDA, Compounding and WADA Status

Tirzepatide's FDA status, compounding rules and anti-doping status, with a dated timeline of every change we track.

Medically reviewed by Juan Pablo Frías, MD · · DisclosureGLP-1 / GIP dual agonistUpdated
FDA status
Approved (Mounjaro, Zepbound)
PCAC vote
Not reviewed
not on the Jul 2026 PCAC agenda
WADA
Not listed
2026 Prohibited List
Not legal adviceStatus reflects public FDA and WADA records on the date shown. Rules differ by country and state.

Current status

FDA approved (Mounjaro, Zepbound)

Tirzepatide is FDA approved (Mounjaro, Zepbound). Products sold as research chemicals are not the approved drug and are not checked by the FDA.

Tirzepatide: regulatory status by country
CountryStatusSource
United StatesApprovedApproved by FDA as Mounjaro (original approval 13 May 2022) and Zepbound (original approval 8 Nov 2023), both tirzepatide, Eli Lilly. Mounjaro is indicated for type 2 diabetes; Zepbound for chronic weight management and obstructive sleep apnea (see label quotes).api.fda.govchecked 2 Oct 2026

Timeline

  1. FDA warning letters to five research-peptide sellersEnforcement
  2. FDA proposes excluding semaglutide, tirzepatide and liraglutide from the 503B bulks listFDA
  3. Seven FDA warning letters to online sellers of GLP-1 productsEnforcement
Every peptide on the FDA tracker

Compounding and research-use sellers

  • Category 2 is the FDA's list of bulk substances it flagged as raising significant safety concerns. Compounding pharmacies are not expected to compound from them while they are on it.
  • The Pharmacy Compounding Advisory Committee (PCAC) advises the FDA on which substances belong on the 503A bulks list that pharmacies may compound from. Its votes are advice; the FDA decides.
  • "Research use only" products are sold outside these rules and are not checked by the FDA for identity, purity or dose.

Sport and drug testing

Not on the WADA Prohibited List

GLP-1 and GIP agonists are not named anywhere on the 2026 list. This one is an approved medicine, so the catch-all S0 (which only covers drugs with no approval anywhere) does not apply to it.

Outside the US

Rules differ by country. What each regulator's own records show, with the date we checked:

Tirzepatide: regulatory status by country
CountryStatusSource
United KingdomApprovedListed on emc as Mounjaro KwikPen (tirzepatide), Eli Lilly and Company Limited.medicines.org.ukchecked 2 Oct 2026
CanadaApprovedHealth Canada DPD lists Mounjaro (tirzepatide) as Marketed; Zepbound also marketed.health-products.canada.cachecked 2 Oct 2026
AustraliaApprovedRegistered in the ARTG (TGA search for "tirzepatide" on 2 Oct 2026).tga.gov.auchecked 2 Oct 2026
European UnionApprovedCentrally authorised in the EU as Mounjaro (tirzepatide).ema.europa.euchecked 2 Oct 2026

Two brands, two indications, one molecule

Drugs@FDA lists Zepbound under application NDA217806, sponsor Eli Lilly, with an original approval date of 20231108.[2]

Mounjaro’s label indication is glycemic control in adults and in pediatric patients 10 years of age and older with type 2 diabetes.[10]

Zepbound’s label covers weight reduction and, separately, moderate to severe obstructive sleep apnea in adults with obesity.[11]

Compounded tirzepatide in 2026

On April 30, 2026 FDA proposed to exclude tirzepatide, along with semaglutide and liraglutide, from the 503B bulks list, saying it found no clinical need for outsourcing facilities to compound it.[12]

The comment period ran to June 29, 2026, and FDA said it would consider comments before a final determination, so the exclusion was still a proposal in the cached release.[12]

FDA also stated that tirzepatide and semaglutide do not currently appear on the 503B bulks list or on its drug shortage list.[13]

Warning letters naming tirzepatide

An August warning letter listed tirzepatide first among the unapproved new drugs found on a seller’s website.[14]

A March letter took issue with a seller’s relabelling of tirzepatide as a “GLP-2 Peptide” while listing weight-management benefits.[15]

Abroad and in sport

In Europe, Mounjaro is centrally authorised under product number EMEA/H/C/005620.[6]

The S0 catch-all in WADA’s list covers only substances with no approval anywhere, so an approved drug such as tirzepatide falls outside it.[1]

Common questions

Is tirzepatide FDA approved?

Yes. Drugs@FDA lists Zepbound as a prescription tirzepatide product with an original approval date of 20231108; Mounjaro is the other brand.[2]

Is Tirzepatide legal to buy?

As an approved drug it requires a prescription in the US. Products sold online as research chemicals "not for human use" are not the approved drug.

Is Tirzepatide banned by WADA?

No. GLP-1 and GIP agonists are not named anywhere on the 2026 list. This one is an approved medicine, so the catch-all S0 (which only covers drugs with no approval anywhere) does not apply to it.

Is tirzepatide legal in the US?

Yes, as a prescription medicine: FDA's database lists Zepbound under NDA217806 with prescription marketing status. Tirzepatide sold outside an approval is treated differently, as the warning-letter section above explains.[2]

Is Zepbound FDA approved?

Yes. The Zepbound label states its weight indication for adults with obesity or overweight with a weight-related condition.[11]

Is it legal to sell tirzepatide online?

Not for unapproved products: FDA treats unapproved tirzepatide sold for human use as an unapproved new drug, and introducing it into interstate commerce violates sections 301(d) and 505(a) of the FD&C Act. The approved brands are prescription medicines (see the FAQ above).[14]

Tirzepatide news: what changed this year?

This year's moves were FDA's April 30 proposal to exclude tirzepatide from the 503B bulks list and the August warning letters to sellers.[12]

Which tirzepatide is not FDA approved?

Compounded and other unapproved versions; the approved products are Mounjaro and Zepbound. FDA says unapproved versions of GLP-1 drugs, tirzepatide included, skip its review for safety, effectiveness and quality, and it tells patients to fill prescriptions at a state-licensed pharmacy.[16]

What do the tirzepatide labels list as contraindications?

The Zepbound label lists a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN 2), and known serious hypersensitivity to tirzepatide or its excipients.[11]

More on Tirzepatide

Sources

  1. 1World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
  2. 2United States: Approved by FDA as Mounjaro (original approval 13 May 2022) and Zepbound (original approval 8 Nov 2023), both tirzepatide, Eli Lilly. Mounjaro is indicated for type 2 diabetes; Zepbound for chronic weight management and obstructive sleep apnea (see label quotes).U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026
  3. 3United Kingdom: Listed on emc as Mounjaro KwikPen (tirzepatide), Eli Lilly and Company Limited.Electronic Medicines Compendium (UK) · 2026medicines.org.ukAccessed 2 Oct 2026
  4. 4Canada: Health Canada DPD lists Mounjaro (tirzepatide) as Marketed; Zepbound also marketed.Health Canada · 2026health-products.canada.caAccessed 2 Oct 2026
  5. 5Australia: Registered in the ARTG (TGA search for "tirzepatide" on 2 Oct 2026).Therapeutic Goods Administration (Australia) · 2026tga.gov.auAccessed 2 Oct 2026
  6. 6European Union: Centrally authorised in the EU as Mounjaro (tirzepatide).European Medicines Agency · 2026ema.europa.euAccessed 2 Oct 2026
  7. 7FDA warning letters to five research-peptide sellersFDA warning letter (NuScience Peptides; 1 of 5) · 2026fda.govAccessed 2 Oct 2026
  8. 8FDA proposes excluding semaglutide, tirzepatide and liraglutide from the 503B bulks listFDA · 2026fda.govAccessed 2 Oct 2026
  9. 9Seven FDA warning letters to online sellers of GLP-1 productsFDA warning letter (Gram Peptides; 1 of 7) · 2026fda.govAccessed 2 Oct 2026
  10. 10MOUNJARO prescribing information (FDA label)FDA label, DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
  11. 11ZEPBOUND prescribing information (FDA label)FDA label, DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
  12. 12Official web pageOfficial web page · web page
  13. 13Official web pageOfficial web page · web page
  14. 14Official web pageOfficial web page · web page
  15. 15Official web pageOfficial web page · web page
  16. 16Official web pageOfficial web page · web page

Found an error? Report a correction.